Skip Page Header

Home > Control of 1-benzylpiperazine (BZP) and related compounds.

Advisory Council on the Misuse of Drugs. (2009) Control of 1-benzylpiperazine (BZP) and related compounds. London: Home Office.

[img]
Preview
PDF (1-benzylpiperazine (BZP) report) - Published Version
98kB

BZP is a recreational stimulant, which gained popularity in some countries in the early 2000’s as a legal alternative to amphetamine, methylamphetamine, and 3, 4-methylenedioxy-N-methylamphetamine (MDMA - ecstasy). BZP is a central nervous system (CNS) stimulant with about 10% of the potency of d-amphetamine.

The UK ACMD considers that the harms and misuse of BZP and substituted piperazines (identified in Annex 4) are commensurate with Class C, under Schedule 2, part III, of the Misuse of Drugs Act (1971); and should be scheduled under Schedule I of the Misuse of Drugs Regulations (2001) (having no recognised medicinal use).


Item Type
Report
Publication Type
International, Report
Drug Type
CNS stimulants, New psychoactive substance
Intervention Type
Harm reduction, Policy
Date
2009
Pages
19 p.
Publisher
Home Office
Corporate Creators
Advisory Council on the Misuse of Drugs
Place of Publication
London
EndNote
Accession Number
HRB (Electronic Only)
Related (external) link

Repository Staff Only: item control page